Insulet (Nasdaq:PODD) announced today that it received FDA 510(k) clearance for new enhancements to its Omnipod 5 system.

MannKind (Nasdaq:MNKD) announced that the FDA accepted a supplemental New Drug Application (sNDA) for its Furoscix ReadyFlow ...

Insulet (Nasdaq:PODD) today announced immediate compatibility between its Omnipod 5 system and the Dexcom (Nasdaq:DXCM) G7 15 ...

Medtronic (NYSE:MDT) announced the full U.S. launch for its Instinct sensor, made by Abbott, paired with the MiniMed 780G ...

Ripple Therapeutics announced today that it entered into a deal with a Bausch + Lomb affiliate related to drug delivery ...

Embecta (Nasdaq:EMBC) today posted fourth-quarter financial results that proved mixed compared to the consensus forecast on ...

PreEvnt aims for Isaac to help people with type 1, type 2 and pre-diabetes, reducing the need for or frequency of ...

Abbott (NYSE:ABT) announced today that it issued a device correction for certain FreeStyle Libre 3 and Libre 3 Plus sensors ...

Insulet (Nasdaq:PODD) today revealed plans for its innovation pipeline, which includes the next-generation Omnipod 6 system.

Insulet (Nasdaq:PODD) today hosted its Investor Day event, led by CEO Ashley McEvoy, laying out the future for the insulin ...

Dexcom announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next month.

Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer.